Top

Published in:

01-10-2009 | Case Report

Successful twin pregnancy while on cyclophosphamide therapy in a patient with lupus nephritis

Authors: Rajiva Gupta, S. Deepanjali, M. M. Thabah, P. Kaur, S. Gupta

Published in: Rheumatology International | Issue 12/2009

Excerpt

Intravenous pulse cyclophosphamide is the standard therapy for the treatment of lupus nephritis [1]. Menstrual irregularities and premature ovarian failure can result from the prolonged use of cyclophosphamide [2, 3]. The teratogenic potential of cyclophosphamide has also been reported [4], and its effect has been proven in humans [5]. Its effect on pregnancy outcomes has not been studied well. We report a case of successful twin pregnancy during treatment with cyclophosphamide in a patient with lupus nephritis. …

Steinberg AD, Steinberg SC (1991) Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 34:945–950. doi:10.1002/art.1780340803 PubMedCrossRef

Wang CL, Wang F, Bosco JJ (1995) Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus 4:11–14. doi:10.1177/096120339500400103 PubMedCrossRef

Boumpas DT, Austin HA, Vaughan EM et al (1993) Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119:366–369PubMed

Enns GM, Roeder E, Chan RT et al (1999) Apparent cyclophosphamide (Cytoxan) embryopathy: a distinct phenotype? Am J Med Genet 86:237–241. doi:10.1002/(SICI)1096-8628(19990917)86:3<237::AID-AJMG8>3.0.CO;2-V PubMedCrossRef

Koren G, Pastuszak A, Ito S (1998) Drugs in pregnancy. N Engl J Med 338:1128–1137. doi:10.1056/NEJM199804163381607 PubMedCrossRef

Austin HA, Klippel JH, Balow JE et al (1986) Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614–619PubMed

Park MC, Park YB, Jung SY et al (2004) Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus 13:569–574. doi:10.1191/0961203304lu1063oa PubMedCrossRef

Huong DL, Amoura Z, Duhaut P et al (2002) Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol 9:2571–2576

Medeiros MM, Silveira VA, Menezes AP et al (2001) Risk factors for ovarian failure in patients with systemic lupus erythematosus. Braz J Med Biol Res 34:1561–1568. doi:10.1590/S0100-879X2001001200008 PubMedCrossRef

10.

Mok CC, Lau CS, Wong RW (1998) Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 41:831–837. doi:10.1002/1529-0131(199806)41:6<1090::AID-ART16>3.0.CO;2-6 PubMedCrossRef

11.

Katsifis GE, Tzioufas AG (2004) Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus 13:673–678. doi:10.1191/0961203304lu2012oa PubMedCrossRef

12.

Matsukawa Y, Nishinarita S, Horie T et al (1998) Successful child bearing during intravenous cyclophosphamide therapy in a patient with systemic lupus erythematosus. Br J Rheumatol 37:342–343. doi:10.1093/rheumatology/37.3.342 PubMedCrossRef

13.

Kart Koseoglu H, Yucel AE, Kunefeci G et al (2001) Cyclophosphamide therapy in a serious case of lupus nephritis during pregnancy. Lupus 10:818–820. doi:10.1177/096120330101001110 PubMedCrossRef

14.

Clowse ME, Magder L, Petri M (2005) Cyclophosphamide for lupus during pregnancy. Lupus 14:593–597. doi:10.1191/0961203305lu2169oa PubMedCrossRef

15.

Zemlickis D, Lishner M, Erlich R et al (1993) Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide. Teratog Carcinog Mutagen 13:139–143. doi:10.1002/tcm.1770130304 PubMedCrossRef

Title: Successful twin pregnancy while on cyclophosphamide therapy in a patient with lupus nephritis
Authors: Rajiva Gupta
S. Deepanjali
M. M. Thabah
P. Kaur
S. Gupta
Publication date: 01-10-2009
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 12/2009
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-009-0860-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Successful twin pregnancy while on cyclophosphamide therapy in a patient with lupus nephritis

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 12/2009

A case of ochronosis with gout and monckeberg arteries

Massive lower gastrointestinal haemorrhage, successfully treated with corticosteroids, as main symptom of Schönlein-Henoch purpura

Serum levels of anti-cyclic citrullinated peptide antibodies are associated with a beneficial response to traditional herbal medicine (Kampo) in rheumatoid arthritis

Two distinct patterns of ankylosing spondylitis in Moroccan patients

The expression of PADI4 in synovium of rheumatoid arthritis

Rituximab in life threatening antisynthetase syndrome

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page